Posted in: information

166 million! Mike biology wholly-owned acquisition of Da microorganism | digital PCR instrument and reagent development strategic cooperation reached

The semi annual report shows that Mike bio spent 166 million yuan to complete the acquisition of 100%equity of Beijing Da Microbial Technology Co., Ltd. (hereinafter referred to as”Da microbial”). In November 2020, Da micro opened the PREA round of financing. Mike bio once subscribed for 3.4722%equity of Da micro with 5million yuan. At the same time, the two sides launched strategic cooperation on the supporting development of digital PCR instruments and reagents.

It is reported that Da microorganism has established the international first chip free digital PCR instrument platform, and has original and independent intellectual property rights. This core technology realizes a new vibrating droplet generation method, which can quickly and efficiently complete the whole process of digital PCR without any chip structure, making the digital PCR technology truly feasible for clinical application.

On July 15, Mike bio disclosed the first semi annual report of Shenzhen stock market. In the first half of the year, the company achieved an operating revenue of 1.782 billion yuan, a year-on-year decrease of 9.11%; The net profit attributable to the parent company was 406 million yuan, a year-on-year decrease of 23.68%; The basic earnings per share is 0.6728 yuan. Among them, the sales revenue of independent products was 1.136 billion yuan, a year-on-year decrease of 1.84%, and the sales revenue of agency products was 626 million yuan, a year-on-year decrease of 20.17%.

In the report, Mike bio pointed out that with the continuous improvement of the company’s ability of independent products, and the cost advantage of independent products is much higher than that of agency products, the company has adjusted its business structure. In recent years, the company’s independent products have maintained rapid growth, and their proportion in sales revenue has increased rapidly. During the reporting period, the proportion of independent product sales increased from 57.77%to 63.73%. However, due to the impact of centralized purchase and price reduction, the sales revenue of molecular nucleic acid detection products in independent products in the first half of 2022 decreased by 12.96%year-on-year, and the gross profit margin decreased by 19.02 percentage points. The changes in product structure and profitability drove the overall revenue and gross profit margin of independent products to decline slightly. At the same time, the company accelerated the adjustment of business structure, especially the substitution and divestiture of agency products, and the sales revenue and gross profit margin of agency products showed an accelerated downward trend.

In terms of R & D, as of the end of the reporting period, the company had 853 R & D personnel, accounting for 29.77%of the total number of employees. There were 404 R & D personnel above middle and senior levels, including 49 senior and above core R & D teams; During the reporting period, the R & D investment was 123 million yuan, an increase of 10.94%over the same period last year. The company added 24 domestic product registration certificates, and by the end of the reporting period, it had obtained 440 domestic product registration certificates, including 128 biochemical products, 177 immune products, 82 clinical tests (including blood cells, coagulation, blood type, urine, pathology), 10 molecular products, 23 rapid tests, and 20 instrument products.